FY2025 · ended Dec 27, 2025 · Revenue $4.02B, -0.9% YoY · Filed Feb 18, 2026
Charles River Laboratories International, Inc. (CRL) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 27, 2025, it reported revenue of $4.0 billion and a net loss of $144.3 million. Free cash flow was $518.5 million. As of Sep 26, 2026 it held $200.4 million in cash and investments and $417.1 million in total debt.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- CRL (NYSE)
- Fiscal year ends
- December 27
- Headquarters
- Wilmington, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1100682
- Former names
- CHARLES RIVER LABORATORIES INTERNATIONAL INC (until May 30, 2019); CHARLES RIVER LABORATORIES HOLDINGS INC (until Jan 28, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 27, 2025 |
FY 2024 Dec 28, 2024 |
FY 2023 Dec 30, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 25, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.0B | $4.0B | $4.1B | $4.0B | $3.5B |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M |
| Net income | -$144.3M | $22.2M | $474.6M | $486.2M | $391.0M |
| Diluted EPS | -$2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Operating cash flow | $737.6M | $734.6M | $683.9M | $619.6M | $760.8M |
| Free cash flow | $518.5M | $501.6M | $365.4M | $294.9M | $532.0M |
| Total assets | $7.1B | $7.5B | $8.2B | $7.6B | $7.0B |
| Total liabilities | $3.9B | $4.0B | $4.5B | $4.6B | $4.4B |
| Stockholders' equity | $3.2B | $3.5B | $3.6B | $3.0B | $2.5B |
| Cash and investments | $213.8M | $194.6M | $276.8M | $233.9M | $242.3M |
| Total debt | $519.8M | $566.5M | $505.9M | $468.3M | $313.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 11, 2026 | May 5, 2026 |
All 1005 Charles River Laboratories International, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.